Comparative Risk of Incident Autoimmune Diseases by First Add-on Antidiabetic Drug Class After Metformin: A Population-Based Active-Comparator, New-User Cohort Study

Purpose To compare the incidence of autoimmune rheumatic diseases among patients with type 2 diabetes initiating different oral glucose-lowering drug classes as the first add-on to metformin. Methods This active-comparator, new-user cohort study used the Korean National Health Insurance Service–National Sample Cohort. Adults who initiated metformin monotherapy and subsequently added a dipeptidyl peptidase-4 (DPP-4) inhibitor, sodium–glucose cotransporter-2 (SGLT-2) inhibitor, sulfonylurea, or thiazolidinedione between January 2014 and June 2023 were included. Patients with a history of autoimmune rheumatic disease were excluded. The primary outcome was incident autoimmune rheumatic disease identified using diagnostic codes. Multivariable Cox regression was used to estimate adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs), with DPP-4 inhibitors as the reference. Results The cohort included 14,463 patients: 9,279 receiving DPP-4 inhibitors, 2,339 receiving SGLT-2 inhibitors, 2,434 receiving sulfonylureas, and 411 receiving thiazolidinediones. The incidence rates of autoimmune rheumatic disease were 15.32, 13.16, 16.67, and 10.97 per 1,000 person-years, respectively. Compared with DPP-4 inhibitors, SGLT-2 inhibitors were associated with lower risks of autoimmune rheumatic disease (aHR, 0.80; 95% CI, 0.65–0.99) and rheumatoid arthritis (aHR, 0.79; 95% CI, 0.63–0.99). The corresponding aHRs for overall autoimmune rheumatic disease were 1.11 (95% CI, 0.94–1.29) for sulfonylureas and 0.65 (95% CI, 0.42–1.01) for thiazolidinediones. Conclusion Among patients adding a second oral agent to metformin, SGLT-2 inhibitor initiation was associated with a lower incidence of autoimmune rheumatic disease than DPP-4 inhibitor initiation. Residual confounding and claims-based outcome ascertainment limit causal interpretation.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11564075/v1
Primary Topic
Diabetes Treatment and Management
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Comparative Risk of Incident Autoimmune Diseases by First Add-on Antidiabetic Drug Class After Metformin: A Population-Based Active-Comparator, New-User Cohort Study

Yil‐Seob Lee, Hyounggyoon Yoo, Wonsuk Shin, Seung‐Hun You
4 links
Research Square
Diabetes Treatment and Management
preprint

Comparative Risk of Incident Autoimmune Diseases by First Add-on Antidiabetic Drug Class After Metformin: A Population-Based Active-Comparator, New-User Cohort Study

Yil‐Seob Lee, Hyounggyoon Yoo, Wonsuk Shin, Seung‐Hun You
preprint en

Abstract

Purpose To compare the incidence of autoimmune rheumatic diseases among patients with type 2 diabetes initiating different oral glucose-lowering drug classes as the first add-on to metformin. Methods This active-comparator, new-user cohort study used the Korean National Health Insurance Service–National Sample Cohort. Adults who initiated metformin monotherapy and subsequently added a dipeptidyl peptidase-4 (DPP-4) inhibitor, sodium–glucose cotransporter-2 (SGLT-2) inhibitor, sulfonylurea, or thiazolidinedione between January 2014 and June 2023 were included. Patients with a history of autoimmune rheumatic disease were excluded. The primary outcome was incident autoimmune rheumatic disease identified using diagnostic codes. Multivariable Cox regression was used to estimate adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs), with DPP-4 inhibitors as the reference. Results The cohort included 14,463 patients: 9,279 receiving DPP-4 inhibitors, 2,339 receiving SGLT-2 inhibitors, 2,434 receiving sulfonylureas, and 411 receiving thiazolidinediones. The incidence rates of autoimmune rheumatic disease were 15.32, 13.16, 16.67, and 10.97 per 1,000 person-years, respectively. Compared with DPP-4 inhibitors, SGLT-2 inhibitors were associated with lower risks of autoimmune rheumatic disease (aHR, 0.80; 95% CI, 0.65–0.99) and rheumatoid arthritis (aHR, 0.79; 95% CI, 0.63–0.99). The corresponding aHRs for overall autoimmune rheumatic disease were 1.11 (95% CI, 0.94–1.29) for sulfonylureas and 0.65 (95% CI, 0.42–1.01) for thiazolidinediones. Conclusion Among patients adding a second oral agent to metformin, SGLT-2 inhibitor initiation was associated with a lower incidence of autoimmune rheumatic disease than DPP-4 inhibitor initiation. Residual confounding and claims-based outcome ascertainment limit causal interpretation.

Research Square
CHA University Bundang Medical Center (KR)
Good health and well-being
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon